Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Mersana Therapeutics, Inc. (MRSN : NSDQ)
 
 • Company Description   
Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

Number of Employees: 102

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.29 Daily Weekly Monthly
20 Day Moving Average: 2,733,112 shares
Shares Outstanding: 124.63 (millions)
Market Capitalization: $36.08 (millions)
Beta: 0.79
52 Week High: $2.83
52 Week Low: $0.26
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -21.40% -25.65%
12 Week 10.75% -7.09%
Year To Date -79.75% -81.04%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
840 MEMORIAL DRIVE
-
CAMBRIDGE,MA 02139
USA
ph: 617-498-0020
fax: -
jason.fredette@mersana.com http://www.mersana.com
 
 • General Corporate Information   
Officers
Martin Huber - Chief Executive Officer and President
David Mott - Chairman of the Board
Brian DeSchuytner - Chief Operating Officer and Senior Vice President
Ashish Mandelia - Vice President and Chief Accounting Officer
Lawrence M. Alleva - Director

Peer Information
Mersana Therapeutics, Inc. (CORR.)
Mersana Therapeutics, Inc. (RSPI)
Mersana Therapeutics, Inc. (CGXP)
Mersana Therapeutics, Inc. (BGEN)
Mersana Therapeutics, Inc. (GTBP)
Mersana Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 59045L106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 124.63
Most Recent Split Date: (:1)
Beta: 0.79
Market Capitalization: $36.08 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.59 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 1.06
EPS Growth
vs. Year Ago Period: -18.75%
vs. Previous Quarter: -72.73%
Sales Growth
vs. Year Ago Period: -70.21%
vs. Previous Quarter: -83.17%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -990.16
ROA
06/30/25 - -
03/31/25 - -48.87
12/31/24 - -40.01
Current Ratio
06/30/25 - -
03/31/25 - 1.83
12/31/24 - 2.19
Quick Ratio
06/30/25 - -
03/31/25 - 1.83
12/31/24 - 2.19
Operating Margin
06/30/25 - -
03/31/25 - -217.63
12/31/24 - -170.86
Net Margin
06/30/25 - -
03/31/25 - -217.63
12/31/24 - -170.86
Pre-Tax Margin
06/30/25 - -
03/31/25 - -216.41
12/31/24 - -169.82
Book Value
06/30/25 - -
03/31/25 - -0.25
12/31/24 - -0.08
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©